Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study (vol 25, pg e1930, 2020)

被引：0
|
作者：
Frass, Michael
机构：
来源：
ONCOLOGIST | 2024年 / 29卷 / 11期
关键词：
D O I：
10.1093/oncolo/oyae253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e1631 / e1632
页数：2
相关论文
共 50 条
  • [21] Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial)
    Coats, Andrew J. Stewart
    Ho, Gwo Fuang
    Prabhash, Kumar
    von Haehling, Stephan
    Tilson, Julia
    Brown, Richard
    Beadle, John
    Anker, Stefan D.
    JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2016, 7 (03) : 355 - 365
  • [22] Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients
    Xu, Ling
    Li, HeGen
    Xu, ZhenYe
    Wang, ZhongQi
    Liu, LingShuang
    Tian, JianHui
    Sun, JianLi
    Zhou, Lei
    Yao, YiLin
    Jiao, LiJing
    Su, Wan
    Guo, HuiRu
    Chen, PeiQi
    Liu, JiaXiang
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2012, 12
  • [23] Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients
    Ling Xu
    HeGen Li
    ZhenYe Xu
    ZhongQi Wang
    LingShuang Liu
    JianHui Tian
    JianLi Sun
    Lei Zhou
    YiLin Yao
    LiJing Jiao
    Wan Su
    HuiRu Guo
    PeiQi Chen
    JiaXiang Liu
    BMC Complementary and Alternative Medicine, 12
  • [24] Multicenter randomized double-blind controlled phase III study of hhpg-19K as prophylactic therapy in patients with advanced non-small cell lung cancer (NSCLC) receiving myelosuppressive chemotherapy
    Zhou, Caicun
    Huang, Yunchao
    An, Changshan
    Wang, Donglin
    He, Jianxing
    Zhou, Fuxiang
    Chen, Gongyan
    Li, Yali
    Wu, Changping
    Wu, Gang
    Song, Xia
    Gao, Jianfei
    Liu, Wei
    Li, Baolan
    Shi, Jianhua
    Huang, Cheng
    Yu, Ping
    Feng, Jueping
    Liu, Yi
    Xia, Jielai
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
    Boyer, Michael
    Hui, Rina
    Urban, Damien
    Clingan, Philip
    Su, Wu-Chou
    Devaux, Celine
    Gadgeel, Shirish
    Garassino, Marina
    Leopold, Lance
    Daniel, Jeannie
    Munteanu, Mihaela C.
    Samkari, Ayman
    Luo, Yiwen
    Abreu, Delvys Rodriguez
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [26] BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer
    Zhou, Caicun
    Wu, Yi-Long
    Chen, Gongyan
    Liu, Xiaoqing
    Zhu, Yunzhong
    Lu, Shun
    Feng, Jifeng
    He, Jianxing
    Han, Baohui
    Wang, Jie
    Jiang, Guoliang
    Hu, Chunhong
    Zhang, Hao
    Cheng, Gang
    Song, Xiangqun
    Lu, You
    Pan, Hongming
    Zheng, Wenjuan
    Yin, Anny-Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (19) : 2197 - U108
  • [27] A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naive metastatic/unresectable non-small cell lung cancer
    Reck, Martin
    Krzakowski, Maciej
    Chmielowska, Ewa
    Sebastian, Martin
    Hadler, Dietrich
    Fox, Tara
    Wang, Qiang
    Greenberg, Jon
    Beckman, Robert A.
    von Pawel, Joachim
    LUNG CANCER, 2013, 82 (03) : 441 - 448
  • [28] A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ONARTUZUMAB (METMAB) IN COMBINATION WITH PACLITAXEL plus CISPLATIN (OR CARBOPLATIN) AS FIRST-LINE TREATMENT FOR PATIENTS (PTS) WITH STAGE IIIB OR IV SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Hirsch, F. R.
    Gandara, D.
    Govindan, R.
    Paton, V. E.
    Yu, W.
    ANNALS OF ONCOLOGY, 2012, 23 : 445 - 445
  • [29] A multicenter, randomized, double-blind, placebo controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.
    Zhang, Li
    Zhou, Ting
    Ma, Yuxiang
    Yang, Yunpeng
    Fang, Wenfeng
    Zhao, Yuangyuan
    Hong, Shaodong
    Fang, Chan
    Zhang, Jiexia
    Zhang, Hongyu
    Zhao, Hongyun
    Huang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC)
    Scagliotti, G.
    Vynnychenko, I.
    Ichinose, Y.
    Park, K.
    Kubota, K.
    Blackhall, F. H.
    Pirker, R.
    Galiulin, R.
    Ciuleanu, T.
    Sydorenko, O.
    Dediu, M.
    Papai-Szekely, Z.
    Banaclocha, N. Martinez
    McCoy, S.
    Yao, B.
    Hei, Y. J.
    Spigel, D. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345